You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. RFA-DA-25-053: Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R41/R42 Clinical Trials Not Allowed)

    Release Date: 01-29-2024Open Date: 06-25-2024Due Date: 07-25-2024Close Date: 07-26-2024

    Background: Drug discovery and development is a high-cost, high-risk, and time-consuming endeavor where the failure rate of therapeutic candidates that enter clinical trials is 90%. Because of this, in recent years, artificial intelligence (AI), including machine learning (ML) technologies, has been embraced to reduce clinical failure rates and to speed up drug discovery. AI/ML technologies are u ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. PAR-21-282: Blueprint Medtech: Small Business Translator (U44- Clinical Trial Optional)

    Release Date: 08-20-2021Open Date: 09-20-2021 Due Dates: Multiple Close Date: 06-21-2024

    Blueprint MedTech The NIH Blueprint for Neuroscience Research is a collaborative framework through which 14 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders (for further information, see http://neuroscienceblueprint.nih.gov/). Innovators developing groundbreaking medical ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. PAR-24-107: Solutions to Enable Regional Genomic Medicine eConsult Services (R41/R42 Clinical Trial Optional)

    Release Date: 01-09-2024Open Date: 04-30-2024Due Date: 05-30-2024Close Date: 05-31-2024

    Purpose This Notice of Funding Opportunity (NOFO) invites applications from eligible small businesses to develop solutions for commercialization that can be used to enable regional clinician-to-clinician genomic medicine eConsult services. Specifically, we seek products, such as technologies or services, that will allow for the development and sustainment of eConsult services. Eligible United Sta ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. RFA-AA-24-001: High-Throughput Screening (HTS) Platform for Discovery of Medications to Treat Alcohol Use Disorder (R43/R44 Clinical Trials Not Allowed)

    Release Date: 12-21-2023Open Date: 03-05-2024Due Date: 04-09-2024Close Date: 04-10-2024

    Drug development is challenging, particularly for Central Nervous System (CNS) medications. It takes approximately 18 years to move a potential CNS medication from its initial discovery phase to the marketplace, often costing several billion dollars. The failure rate is high (only 8% of new CNS compounds entering Phase I studies will reach the market) and contributes to the high costs and slow rat ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. RFA-AA-24-002: High-Throughput Screening (HTS) Platform for Discovery of Medications to Treat Alcohol Use Disorder (R41/R42 Clinical Trials Not Allowed)

    Release Date: 12-21-2023Open Date: 03-05-2024Due Date: 04-09-2024Close Date: 04-10-2024

    Drug development is challenging, particularly for Central Nervous System (CNS) medications. It takes approximately 18 years to move a potential CNS medication from its initial discovery phase to the marketplace, often costing several billion dollars. The failure rate is high (only 8% of new CNS compounds entering Phase I studies will reach the market) and contributes to the high costs and slow rat ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. PAR-21-233: Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

    Release Date: 04-23-2021Open Date: 07-10-2021 Due Dates: Multiple Close Date: 04-06-2024

    A. Overview Recent advances in biology offer unprecedented opportunities to discover new treatments for nervous system disorders. Biotherapeutic development, however, has inherent complexities with regards to characterization, manufacturing, delivery, and administration. Many academic laboratories and small business enterprises don’t have the full scope of expertise and resources available; thi ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. PAR-21-224: NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)

    Release Date: 05-05-2021Open Date: 08-05-2021 Due Dates: Multiple Close Date: 04-06-2024

    Purpose: To facilitate the cooperation and partnering of public and private funding organizations, universities, academic medical centers, research institutes, contract research organizations, biotechnology companies, and pharmaceutical companies, NINDS has formed the Neurology Network of Excellence in Clinical Trials (NeuroNEXT, www.NeuroNEXT.org). NeuroNEXT has a Clinical Coordinating Center (C ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. PAR-21-267: NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)

    Release Date: 07-16-2021Open Date: 08-07-2021 Due Dates: Multiple Close Date: 04-06-2024

    Purpose NINDS is committed to advancing diagnostics and treatments for people burdened by neurological diseases, and the NINDS Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs have provided the small business community with critical seed funding to support the development of a wide variety of technologies and therapeutics for the diagnosis and treatm ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. PAR-21-265: NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional)

    Release Date: 07-16-2021Open Date: 08-05-2021 Due Dates: Multiple Close Date: 04-06-2024

    Purpose NINDS is committed to advancing diagnostics and treatments for people burdened by neurological diseases, and the NINDS Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs have provided the small business community with critical seed funding to support the development of a wide variety of technologies and therapeutics for the diagnosis and treat ...

    SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health
  10. PAR-21-266: NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)

    Release Date: 07-16-2021Open Date: 08-05-2021 Due Dates: Multiple Close Date: 04-06-2024

    Purpose NINDS is committed to advancing diagnostics and treatments for people burdened by neurological diseases, and the NINDS Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs have provided the small business community with critical seed funding to support the development of a wide variety of technologies and therapeutics for the diagnosis and treat ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government